CHEST 2022
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
CHEST 2022, News
The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.
CHEST 2022
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
CHEST 2022
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
CHEST 2022
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
ATS 2022
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
ATS Virtual Program 2020
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
News
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
AAAAI 2022
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
AAAAI 2022
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?
